Fernwood Investment Management LLC Sells 50 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Fernwood Investment Management LLC decreased its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,275 shares of the biotechnology company’s stock after selling 50 shares during the quarter. Axon Enterprise makes up about 0.8% of Fernwood Investment Management LLC’s investment portfolio, making the stock its 24th largest position. Fernwood Investment Management LLC’s holdings in Axon Enterprise were worth $3,171,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. HB Wealth Management LLC grew its holdings in Axon Enterprise by 3.9% during the 4th quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 43 shares during the last quarter. UMB Bank n.a. grew its holdings in Axon Enterprise by 11.0% during the 4th quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 44 shares during the last quarter. Lindbrook Capital LLC grew its holdings in Axon Enterprise by 43.3% during the 4th quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 52 shares during the last quarter. Greenleaf Trust grew its holdings in Axon Enterprise by 3.6% during the 3rd quarter. Greenleaf Trust now owns 1,540 shares of the biotechnology company’s stock worth $306,000 after acquiring an additional 54 shares during the last quarter. Finally, Czech National Bank grew its holdings in Axon Enterprise by 0.4% during the 4th quarter. Czech National Bank now owns 12,336 shares of the biotechnology company’s stock worth $3,187,000 after acquiring an additional 54 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AXON. Argus began coverage on shares of Axon Enterprise in a research note on Wednesday, March 13th. They issued a “buy” rating and a $380.00 target price on the stock. Robert W. Baird lifted their price objective on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday, February 22nd. Morgan Stanley raised their price objective on Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday. The Goldman Sachs Group boosted their target price on Axon Enterprise from $297.00 to $339.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, StockNews.com lowered Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $314.91.

Axon Enterprise Stock Up 1.6 %

NASDAQ AXON traded up $5.07 during trading hours on Monday, hitting $313.30. 336,173 shares of the company traded hands, compared to its average volume of 465,949. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 3.00. The business’s 50-day moving average is $304.22 and its 200-day moving average is $262.21. The stock has a market capitalization of $23.64 billion, a price-to-earnings ratio of 135.42 and a beta of 0.93. Axon Enterprise, Inc. has a twelve month low of $175.37 and a twelve month high of $329.87.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.29. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The business had revenue of $432.14 million during the quarter, compared to analysts’ expectations of $418.97 million. Sell-side analysts anticipate that Axon Enterprise, Inc. will post 2.44 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.